Skip to main content
. 2016 Jul 20;7(33):53254–53268. doi: 10.18632/oncotarget.10736

Figure 5. Effects of ERCC2 on miR-770-5p-modulated chemoresistance in ovarian cancer cells.

Figure 5

(A) Flow cytometric detection of apoptosis via Annexin V-FITC/PI staining in cisplatin-sensitive A2780S cells after treatment with cisplatin (20 μM) for 48 h after transfection with miR-770-5p inhibitor, negative control, or miR-770-5p inhibitor + siERCC2. (B) After transfection with miR770-5p inhibitor, A2780S cells were treated with cisplatin (40 μM) for 24 h. TUNEL staining indicated that apoptosis decreased after cisplatin treatment in A2780S cells transfected with miR-770-5p inhibitor; siRNA-mediated ERCC2 silencing reversed this effect. Original magnification: 400× (C) Analysis of flow cytometry results (left, n = 10/group) and TUNEL staining (right, n = 6/group). Statistical analyses of percent values and time to 50% apoptosis were conducted using Pearson's χ2 test and ANOVA, respectively. (D) RT-PCR and western blot analysis confirmed that siRNA inhibited the expression of ERCC2 mRNA and protein in A2780 cell lines. p < 0.001.